Figure 7

CycT diminishes heme biosynthesis and degradation, and addition of heme partially reverses the effects of CycT on OCR, cell proliferation, and tumorigenic functions in NSCLC cells. CycT, not the SMO antagonist SANT-1, strongly diminishes heme biosynthesis (A) and degradation (B) in H1299 NSCLC cells. 25 μM CycT and 50 μM SANT-1 were used. Data are plotted as mean ± standard deviation. (C) Addition of heme (10 μM) partially reverses the effect of CycT on oxygen consumption rate (OCR) in H1299 cells. (D) Addition of heme (10 μM) partially reverses the effect of CycT on the proliferation rate of H1299 cells. (E) Addition of heme (10 μM) partially reverses the effect of CycT on migration capability in H1299 cells. (F) Addition of heme (10 μM) partially reverses the effect of CycT on invasion capability in H1299 cells. For statistical analysis, the levels in CycT-treated cells were compared to the levels in untreated cells, and the levels in cells with heme added back were compared to the levels in CycT-treated cells. P-values were calculated with a Welch 2-sample t-test. *p-value < 0.05, **p-value < 0.005 for the difference between CycT-treated and untreated cells; [*] p-value < 0.05 for difference between CycT-treated cells and CycT-treated cells with heme added back.